middle.news
Patrys Advances Injectable Quetiapine for Delirium with Accelerated FDA Pathway
8:28am on Monday 27th of July, 2026 AEST
•
Healthcare
Read Story
Patrys Advances Injectable Quetiapine for Delirium with Accelerated FDA Pathway
8:28am on Monday 27th of July, 2026 AEST
Key Points
Injectable quetiapine reformulation targets >US$2B delirium market
Accelerated FDA 505(b)(2) pathway with 3–5 year timeline
Proprietary patent protection extends to ~2042
Phase 1A trial initiation planned for Q3 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Patrys (ASX:PAB)
OPEN ARTICLE